Elbeddini Ali, To Anthony, Tayefehchamani Yasamin, Wen Cindy Xin
Chairman of the Pharmacy Department, Winchester District Memorial Hospital, 566 Louise Street, Winchester, ON, KK0C2K0, Canada.
Leslie Dan Faculty of Pharmacy, University of Toronto, 144 college st, Toronto, M5S 3M2, Canada.
J Pharm Policy Pract. 2021 Nov 29;14(1):98. doi: 10.1186/s40545-021-00379-8.
Cancer patients are a complex and vulnerable population whose medication history is often extensive. Medication reconciliations in this population are especially essential, since medication discrepancies can lead to dire outcomes. This commentary aims to describe the significance of conducting medication reconciliations in this often-forgotten patient population. We discuss additional clinical interventions that can arise during this process as well. Medication reconciliations provide the opportunity to identify and prevent drug-drug and herb-drug interactions. They also provide an opportunity to appropriately adjust chemotherapy dosing according to renal and hepatic function. Finally, reconciling medications can also provide an opportunity to identify and deprescribe inappropriate medications. While clinical impact appears evident in this landscape, evidence of economic impact is lacking. As more cancer patients are prescribed a combination of oral chemotherapies, intravenous chemotherapies and non-anticancer medications, future studies should evaluate the advantages of conducting medication reconciliations in these patient populations across multiple care settings.
癌症患者是一个复杂且脆弱的群体,他们的用药史往往很长。在这一群体中进行用药核对尤为重要,因为用药差异可能导致严重后果。本评论旨在描述在这个经常被遗忘的患者群体中进行用药核对的重要性。我们还将讨论在此过程中可能出现的其他临床干预措施。用药核对提供了识别和预防药物相互作用以及草药与药物相互作用的机会。它们还提供了根据肾功能和肝功能适当调整化疗剂量的机会。最后,核对用药还可以提供识别和停用不适当药物的机会。虽然临床影响在这种情况下似乎很明显,但缺乏经济影响的证据。随着越来越多的癌症患者被开具口服化疗药物、静脉化疗药物和非抗癌药物的组合,未来的研究应该评估在多个护理环境中的这些患者群体中进行用药核对的优势。